Quarter Comparison
Revenue
Net Margin
EPS (Diluted)
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Abeona Therapeutics ® Reports Second Quarter 2026 Results and Provides Business Update - Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date;
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Abeona Therapeutics ® Reports Second Quarter 2026 Results and Provides Business Update - Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments completed – - Expanding QTC network now includes seven sites nationwide ; growing number of QTCs progressing patients through treatment process – - $146.8 million in cash, cash equivalents and short-term investments as of June 30, 2026 – CLEVELAND, August 13, 2026 – Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2026 and provided an update on commercial execution for ZEVASKYN (prademagene zamikeracel). Commercial Update Steady launch-year growth for ZEVASKYN. Commercial execution continued to strengthen during the...
Source
Exhibit EX-99.1
0001493152-26-037575
Filed August 13, 2026 at 11:30 AM UTC. The figures above are from the audited statements, not from this release.